Rein Therapeutics, Inc. — Operating Income by Fiscal Year
11 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/395f755f-9bc6-4a1c-8c14-7c366c6e2491/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-50.6M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-126385 |
| FY 2024 | $-65.1M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-051566 |
| FY 2023 | $-16.3M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-044508 |
| FY 2022 | $-27.6M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-008767 |
| FY 2021 | $-26.6M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-004774 |
| FY 2020 | $-20.5M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-015115 |
| FY 2019 | $-30.0M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-014155 |
| FY 2018 | $-31.9M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-010007 |
| FY 2017 | $-23.0M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-007403 |
| FY 2016 | $-18.2M | 2016-01-01 – 2016-12-31 | evidence 0001564590-18-007403 |
| FY 2015 | $-12.9M | 2015-01-01 – 2015-12-31 | evidence 0001564590-18-007403 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).